Post Doctoral Researcher

at  University of Oxford

APPLICATION PROCESS

You will be required to upload a CV and Supporting Statement as part of your online application. The Supporting Statement should include a cover letter and should also clearly describe how you meet each of the selection criteria listed in the job description. Click here for information and advice on writing an effective Supporting Statement.
To discuss the post in more detail, please contact Amarjit Bhomra, the Lab Manager using the contact details below.
Only online applications received before 12.00 midday on 25 June 2024 will be considered. Interviews will be held as soon as possible thereafter.

We are seeking candidates to develop a therapy for heritable cardiomyopathies. Specifically, the appointee will be responsible for the preclinical development and selection of an oligonucleotide drug to be tested in a Clinical Trial. The role requires applicants to hold a PhD in a relevant scientific subject. The candidate will lead the preparation of scientific articles and attend conferences to disseminate scientific results.
The successful candidate will join Prof. Matthew Woods’ Group at the Institute of Development and Regenerative Medicine on the Old Road Campus. The laboratory has developed novel oligonucleotide therapies for muscle disorders, including Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy type 1 (DM1), which are currently being tested in clinical trials. Additionally, the group has developed peptide and antibody-based delivery platform technologies for targeted cell delivery and has discovered new delivery technologies.
The position is offered on a full-time basis for a 1-year fixed-term contract, funded by the CureHeart project. CureHeart is a £30m global award funded by the British Heart Foundation. This award represents one of the largest non-commercial grants ever awarded and provides a “once in a generation opportunity” to offer hope to patients and families affected by these deadly diseases. The award aims to develop revolutionary and precise technologies to silence the faulty genes responsible for these conditions. The team includes world-leading scientists from Oxford, Harvard, and other highly prestigious institutions.